Mochi Health Compounded GLP-1 review: is it worth it?

What is Mochi Health and how does it work?

Mochi Health is an online obesity-medicine clinic. You do not visit a physical clinic; the entire process happens through Mochi's app and website. The model works in a few steps:

1. Sign up and intake. You complete a health questionnaire covering weight history, BMI, medical conditions, and current medications.
2. Provider visit. A licensed physician or nurse practitioner reviews your case (Mochi uses live video visits rather than questionnaire-only "async" prescribing for its core program) and determines whether a GLP-1 medication is clinically appropriate, following obesity-treatment guidelines that generally require a BMI of 30 or higher, or 27 or higher with a weight-related condition.
3. Prescription and fulfillment. If approved, your prescription is sent either to a retail pharmacy (for branded, FDA-approved drugs) or to a compounding pharmacy that ships compounded medication to your door.
4. Ongoing care. You get unlimited in-app messaging, scheduled follow-ups, and access to a registered dietitian for nutrition and behavior support.

The defining feature versus a regular doctor's office is the bundling of prescribing, fulfillment, and coaching into one subscription, and the availability of compounded GLP-1s at a fraction of branded list prices.

What medications does Mochi offer, and what is "compounded" GLP-1?

Mochi offers two broad tracks:

• Branded, FDA-approved drugs routed through normal pharmacies: semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), and older agents like liraglutide and the bupropion-naltrexone combination.
• Compounded GLP-1s — custom-made semaglutide and tirzepatide produced by a compounding pharmacy rather than by the brand manufacturer (Novo Nordisk or Eli Lilly).

This distinction is the single most important thing to understand. Compounded semaglutide and tirzepatide are not FDA-approved products. They are pharmacy-prepared versions of the active ingredient. Compounding is normally a legal practice for individualized needs, and during 2023–2024 large-scale compounding of these drugs was permitted because both were on the FDA's official drug-shortage list.

That window has effectively closed. The FDA declared the tirzepatide shortage resolved on October 2, 2024, and the semaglutide shortage resolved on February 21, 2025 (FDA). Following those determinations, the FDA's enforcement-discretion periods for ordinary state-licensed (503A) pharmacies to mass-compound these drugs ended in early 2025 — February 18, 2025 for tirzepatide and April 22, 2025 for semaglutide at 503A pharmacies, with slightly later dates for 503B outsourcing facilities (FDA; NCPA, March 2025). In 2026 the FDA went further, proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list entirely, stating it found no clinical need for outsourcing facilities to make them from bulk drug substance (FDA press announcement, 2026). Legal challenges from the Outsourcing Facilities Association failed to overturn the determinations; courts denied preliminary injunctions.

What this means in plain terms: the broad legal "shortage" justification for cheap compounded GLP-1s is gone. Compounding can still legally occur in narrower circumstances — for example, when a prescriber documents a clinical need for a personalized formulation a patient cannot get from the approved product (such as a specific dose or an allergy to an inactive ingredient). Telehealth companies, including Mochi, have leaned on these individualized-prescribing pathways to keep compounded options available. This is a legitimate gray zone, not a clearly settled one, and it is the central uncertainty for anyone considering the compounded plan.

How well do these GLP-1 medications work?

The efficacy data behind GLP-1 medications is strong — but it comes from trials of the branded, FDA-approved drugs, not from compounded copies.

• Semaglutide (Wegovy): In the pivotal STEP 1 trial of 1,961 adults with overweight or obesity without diabetes, participants on once-weekly 2.4 mg semaglutide lost an average of about 14.9% of body weight at 68 weeks, versus roughly 2.4% on placebo (Wilding et al., NEJM 2021; PMID 33567185).
• Tirzepatide (Zepbound): In SURMOUNT-1, tirzepatide produced average weight reductions of about 15%, 19.5%, and 20.9% at the 5 mg, 10 mg, and 15 mg doses respectively (some Lilly reporting cites up to 22.5% on a complete-case basis), versus about 3% on placebo over 72 weeks (Jastreboff et al., NEJM 2022; PMID 35658024).

These are among the largest weight reductions ever seen with pharmacotherapy. GLP-1 receptor agonists mimic the gut hormone GLP-1, slowing gastric emptying and acting on appetite-regulating centers in the brain to reduce hunger and food intake; tirzepatide adds GIP-receptor activity, which appears to amplify the effect.

The honest caveat for Mochi's compounded plan: compounded semaglutide and tirzepatide use the same active molecule, so the mechanism is identical, but compounded products have not undergone the trials, manufacturing oversight, or FDA approval that produced the numbers above. Potency and purity depend entirely on the compounding pharmacy. The FDA has documented adverse events and dosing errors tied to compounded GLP-1s, and salt forms of semaglutide (semaglutide sodium/acetate) used by some compounders are not the same as the base molecule studied in trials.

How much does Mochi Health cost?

Mochi separates the cost into two charges, which is essential to understand before signing up:

So the realistic all-in cost is roughly $178/month for compounded semaglutide or $278/month for compounded tirzepatide (membership + medication). A reduced-price "Wellness Plus" membership (~$69/month) exists for people using insurance for the medical-nutrition-therapy side. Branded medication, if you choose it, is priced separately and may be covered by insurance — Wegovy and Zepbound carry list prices well over $1,000/month before insurance or manufacturer savings, though Lilly and Novo Nordisk now sell self-pay vials directly at lower prices.

A flat price across all doses is genuinely consumer-friendly: many competitors raise the price as your dose escalates, so Mochi's structure can save money for patients who titrate to higher doses.

The billing pitfall to watch: Mochi bills membership and medication as two separate auto-renewing subscriptions. Cancelling one does not cancel the other. Continued charges after a patient believed they had cancelled is the most common complaint theme in consumer-protection filings against the company. Cancel both, in writing, and confirm.

Is Mochi Health legitimate and safe?

Mochi uses US-licensed prescribers and live video visits, which is more rigorous than questionnaire-only telehealth. But the compounded side of the business has drawn serious, documented safety scrutiny that any prospective patient should know about.

In March 2025, the Washington State Department of Health's Pharmacy Quality Assurance Commission issued a "Limited Stop Service" restriction on the license of Aequita, a Kirkland, Washington compounding pharmacy affiliated with Mochi Health. According to the Commission's March 13, 2025 notice, the pharmacy could not compound, dispense, deliver, or distribute compounded products in Washington until the matter was resolved, after it failed to implement a commission-approved plan of correction. Regulators documented deficiencies including allowing untrained and unqualified staff to perform sterile compounding, failure to properly supervise staff, and not adhering to sterile-compounding procedures meant to ensure product integrity and patient safety (Washington State DOH, March 13, 2025). KING 5 News (Seattle) subsequently reported in early 2026 on whistleblower allegations at the facility — including unlicensed workers handling injectable medication and improper cold-chain shipping — and reporting indicates the Kirkland facility ceased operations and that Mochi shifted fulfillment to other compounding pharmacies.

This does not mean every Mochi prescription is unsafe, and the branded-drug pathway is unaffected. But it is a concrete red flag about the company's compounding supply chain, and it underscores the broader risk of injectable compounded drugs: sterility, potency, and labeling are only as good as the pharmacy producing them, and there is no FDA pre-market verification. The FDA has repeatedly warned consumers about compounded GLP-1 dosing errors and counterfeit products.

If you pursue Mochi's compounded plan, reasonable due diligence includes asking which compounding pharmacy will fill your prescription, whether it is 503A or 503B, where it is licensed, whether the product is base semaglutide/tirzepatide or a salt form, and how the medication is shipped and stored.

Who is Mochi Health best for, and who should skip it?

It may be a reasonable fit if you:

• Cannot get insurance coverage for branded GLP-1s and the ~$178–$278/month compounded route is the only affordable path to treatment.
• Want bundled dietitian and behavioral support, not just a prescription.
• Value a flat medication price as you titrate up.
• Are comfortable doing your own diligence on the compounding pharmacy and accept the legal/safety uncertainty.

You should be cautious or look elsewhere if you:

• Can access branded Wegovy or Zepbound through insurance or manufacturer self-pay programs — the approved products carry the trial evidence and full regulatory oversight, which is worth a great deal for an injectable you take long-term.
• Are uneasy with the documented compounding-pharmacy safety findings or the unsettled legal status of compounded GLP-1s.
• Are pregnant, planning pregnancy, or have a personal or family history of medullary thyroid carcinoma or MEN2, or a history of pancreatitis — GLP-1s carry a boxed warning for thyroid C-cell tumors (seen in rodents) and contraindications that require a real medical evaluation (FDA labeling for Wegovy and Zepbound).

What are the side effects?

GLP-1 side effects are the same regardless of source and are mostly gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort, usually worst during dose escalation and improving over time. More serious but less common risks include pancreatitis, gallbladder disease, and, with rapid dosing, dehydration and kidney injury (FDA labeling). With compounded products there is an added layer of uncertainty: if potency is higher than labeled, the risk of severe nausea, vomiting, and dosing-error harm increases — a pattern the FDA has flagged in compounded-GLP-1 adverse-event reports.

How does Mochi compare to alternatives?

• vs. branded GLP-1 telehealth (e.g., Ro, Hims & Hers, LifeMD routing to Wegovy/Zepbound): Mochi's compounded plan is cheaper, but branded routes give you an FDA-approved product with trial-backed efficacy and known quality.
• vs. other compounded-GLP-1 telehealth (e.g., Henry Meds, Found, various): Mochi competes mainly on flat all-dose pricing and dietitian support, but it carries the specific reputational overhang of the Aequita findings, which several competitors do not.
• vs. buying direct from manufacturers: Eli Lilly (LillyDirect) and Novo Nordisk now sell self-pay vials of their approved drugs, which can be price-competitive with compounded options for some doses while remaining FDA-approved.

The practical comparison usually comes down to: approved drug with oversight at a higher (but falling) price, versus compounded drug at a lower price with materially more uncertainty.

The bottom line

Mochi Health is a legitimately structured telehealth obesity program with real provider visits, dietitian support, and some of the more affordable compounded GLP-1 pricing available, including a consumer-friendly flat price across all doses. The underlying medications — semaglutide and tirzepatide — are backed by some of the strongest weight-loss evidence in medicine (STEP 1, NEJM 2021; SURMOUNT-1, NEJM 2022). The problem is that those data describe the *branded* drugs, while Mochi's headline value rests on *compounded* versions whose legal footing narrowed sharply after the FDA declared the shortages resolved in 2024–2025, and whose supply chain drew a documented state license restriction (a March 2025 "Limited Stop Service") tied to its Kirkland pharmacy. If you can access branded Wegovy or Zepbound affordably, that is the lower-risk path. If compounded is your only realistic option, Mochi can work — but go in with clear eyes about the compounding pharmacy, the dual-subscription billing, and the regulatory uncertainty, and do the diligence the situation demands.